Old drug, new trick: colchicine may stop AFib after heart bypass
NCT ID NCT07611019
First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study tests whether colchicine, a drug usually used for gout, can prevent atrial fibrillation (a type of irregular heartbeat) after coronary artery bypass surgery. About 400 adults scheduled for elective bypass will receive either colchicine or a placebo starting 3 days before surgery and continuing for a week after. The main goal is to see if colchicine reduces the number of people who develop this heart rhythm problem within 14 days after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- colchicine
- What this could lead to
- If it works, this could provide a simple, low-cost way to prevent a common heart-rhythm complication after bypass surgery.
- What could go wrong
- This is an early-to-mid-stage trial with 400 participants, so results may not apply to everyone. Colchicine can cause side effects like stomach upset or, rarely, more serious issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-OPERATIVE ATRIAL FIBRILLATION AFTER CORONARY ARTERY BYPASS GRAFTING (CABG) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Taiwan University Hospital
Taipei, 100, Taiwan